Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Top-Institutions - MDSpire

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • By

  • Sandra Susanibar-Adaniya

  • Benjamin A. Derman

  • Adam D. Cohen

  • Dan T. Vogl

  • Shambavi Richard

  • Adriana Rossi

  • Matthew J. Frigualt

  • Andrew J. Yee

  • Binod Dhakal

  • Noffar Bar

  • April 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Immunotherapy

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Cellular Therapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Immunotherapy

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Cellular Therapy

  • #5

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Cellular Therapy

Original Source(s)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar

  • April 28, 2026

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis